Impact of CYP2C19 Metabolizer Status on Patients with ACS Treated with Prasugrel Versus Clopidogrel

Journal of the American College of Cardiology

Volumn 67, Issue 8, 2016, Pages 936-947

  Doll, Jacob A ^a   Neely, Megan L ^b   Roe, Matthew T ^a,b   Armstrong, Paul W ^c   White, Harvey D ^d   Prabhakaran, Dorairaj ^e   Winters, Kenneth J ^f   Duvvuru, Suman ^f   Sundseth, Scott S ^g   Jakubowski, Joseph A ^f   Gurbel, Paul A ^h   Bhatt, Deepak L ⁱ   Ohman, E Magnus ^a,b   Fox, Keith A A ^j  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF ALBERTA   (Canada)

^d AUCKLAND CITY HOSPITAL   (New Zealand)

^e PUBLIC HEALTH FOUNDATION OF INDIA   (India)

^f ELI LILLY AND COMPANY   (United States)

^g Cabernet Pharmaceuticals   (United States)

^h INOVA HEART AND VASCULAR INSTITUTE   (United States)

ⁱ BRIGHAM AND WOMEN S HOSPITAL   (United States)

^j UNIVERSITY OF EDINBURGH   (United Kingdom)

more..

Author keywords

acute coronary syndrome; dual antiplatelet therapy; genetics; platelets

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; CYTOCHROME P450 2C19; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DRUG METABOLITE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRASUGREL; PROTON PUMP INHIBITOR; PURINERGIC P2Y12 RECEPTOR; ANTITHROMBOCYTIC AGENT; DNA; PURINERGIC P2Y RECEPTOR ANTAGONIST; TICLOPIDINE;

ACUTE CORONARY SYNDROME; ADULT; AGED; ALLELE; ARTICLE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; CYP2C19 GENE; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; GENETIC ASSOCIATION; GENETIC SCREENING; GENETIC VARIABILITY; GENOTYPE; HEART DEATH; HEART INFARCTION; HUMAN; LOADING DRUG DOSE; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; OUTCOME ASSESSMENT; PHENOTYPE; PLATELET REACTIVITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UNSTABLE ANGINA PECTORIS; ANALOGS AND DERIVATIVES; BLOOD; BLOOD CLOTTING PARAMETERS; CLINICAL TRIAL; DOSE RESPONSE; FOLLOW UP; GENETIC POLYMORPHISM; GENETICS; METABOLISM; MIDDLE AGED; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ACUTE CORONARY SYNDROME; AGED; ALLELES; CYTOCHROME P-450 CYP2C19; DNA; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; POLYMORPHISM, GENETIC; PRASUGREL HYDROCHLORIDE; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RETROSPECTIVE STUDIES; TICLOPIDINE; TREATMENT OUTCOME;

EID: 84959019884     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2015.12.036     Document Type: Article

References (24)

1. P.A. Gurbel, A.R. Shuldiner, K.P. Bliden, K. Ryan, R.E. Pakyz, and U.S. Tantry The relation between CYP2C19 genotype and phenotype in stented patients on maintenance dual antiplatelet therapy Am Heart J 161 2011 598 604
2. J.M. Siller-Matula, D. Trenk, K. Schrör, and et al. Response variability to P2Y12 receptor inhibitors: expectations and reality J Am Coll Cardiol Intv 6 2013 1111 1128
3. J.-P. Collet, J.-S. Hulot, A. Pena, and et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study Lancet 373 2009 309 317
4. J.L. Mega, S.L. Close, S.D. Wiviott, and et al. Cytochrome P-450 polymorphisms and response to clopidogrel N Engl J Med 360 2009 354 362
5. A.R. Shuldiner, J.R. O'Connell, K.P. Bliden, and et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy JAMA 302 2009 849 857
6. D. Sibbing, J. Stegherr, W. Latz, and et al. Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention Eur Heart J 30 2009 916 922
7. M.V. Holmes, P. Perel, T. Shah, A.D. Hingorani, and J.P. Casas CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis JAMA 306 2011 2704 2714
8. T. Simon, C. Verstuyft, M. Mary-Krause, and et al. Genetic determinants of response to clopidogrel and cardiovascular events N Engl J Med 360 2009 363 375
9. J.L. Mega, T. Simon, J.P. Collet, and et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis JAMA 304 2010 1821 1830
10. J.L. Mega, S.L. Close, S.D. Wiviott, and et al. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes Circulation 119 2009 2553 2560
11. L. Wallentin, C. Varenhorst, S. James, and et al. Prasugrel achieves greater and faster P2Y12 receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease Eur Heart J 29 2008 21 30
12. D.R. Holmes Jr., G.J. Dehmer, S. Kaul, D. Leifer, P.T. O'Gara, and C.M. Stein ACCF/AHA clopidogrel clinical alert: approaches to the FDA "boxed warning": a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association J Am Coll Cardiol 56 2010 321 341
13. M.T. Roe, P.W. Armstrong, K.A.A. Fox, and et al. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization N Engl J Med 367 2012 1297 1309
14. P.A. Gurbel, D. Erlinge, E.M. Ohman, and et al. Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy JAMA 308 2012 1785 1794
15. C.T. Chin, M.T. Roe, K.A.A. Fox, and et al. Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non-ST-segment elevation myocardial infarction: the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial Am Heart J 160 2010 16 22.e1
16. J.L. Mega, S.L. Close, S.D. Wiviott, and et al. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis Lancet 376 2010 1312 1319
17. C. Varenhorst, S. James, D. Erlinge, and et al. Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease Eur Heart J 30 2009 1744 1752
18. G.R. Wilkinson Drug metabolism and variability among patients in drug response N Engl J Med 352 2005 2211 2221
19. M.J. Price, D.J. Angiolillo, P.S. Teirstein, and et al. Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: impact on Thrombosis and Safety (GRAVITAS) trial Circulation 124 2011 1132 1137
20. L. Wallentin, S. James, R.F. Storey, and et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial Lancet 376 2010 1320 1328
21. P.A. Gurbel, and U.S. Tantry Clopidogrel response variability and the advent of personalised antiplatelet therapy. A bench to bedside journey Thromb Haemost 106 2011 265 271
22. P.A. Gurbel, T.O. Bergmeijer, U.S. Tantry, and et al. The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg, prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery disease Thromb Haemost 112 2014 589 597
23. D.L. Bhatt Tailoring antiplatelet therapy based on pharmacogenomics: how well do the data fit? JAMA 302 2009 896 897
24. J.L. Mega, W. Hochholzer, A.L. Frelinger, and et al. Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease JAMA 306 2011 2221 2228